Provider of health and pharmaceutical research and development services intended to focus on the development and commercialisation of treatments for conditions causing chronically poor airflow to the lungs. The company's health and pharmaceutical research and development services include a novel anti-inflammatory/anti-oxidant and an oral bacterial vaccine, form our two-pronged complementary approach to the treatment of Chronic Obstructive Pulmonary Disease (COPD) from its early to severe stages enabling patients to get products for undertreated conditions, primarily those of the airways from the mouth and nose to the lungs.